These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20581581)

  • 1. Treatment of pulmonary epithelioid hemangioendothelioma with bevacizumab.
    Kim YH; Mishima M; Miyagawa-Hayashino A
    J Thorac Oncol; 2010 Jul; 5(7):1107-8. PubMed ID: 20581581
    [No Abstract]   [Full Text] [Related]  

  • 2. Bevacizumab chemotherapy for pulmonary epithelioid hemangioendothelioma with severe dyspnea.
    Mizota A; Shitara K; Fukui T
    J Thorac Oncol; 2011 Mar; 6(3):651-2. PubMed ID: 21317750
    [No Abstract]   [Full Text] [Related]  

  • 3. Pulmonary epithelioid haemangioendothelioma and bevacizumab.
    Belmont L; Zemoura L; Couderc LJ
    J Thorac Oncol; 2008 May; 3(5):557-8. PubMed ID: 18449015
    [No Abstract]   [Full Text] [Related]  

  • 4. Bevacizumab for recurrent hemangioendothelioma.
    Trautmann K; Bethke A; Ehninger G; Folprecht G
    Acta Oncol; 2011 Jan; 50(1):153-4. PubMed ID: 20950228
    [No Abstract]   [Full Text] [Related]  

  • 5. Pazopanib for metastatic pulmonary epithelioid hemangioendothelioma-a suitable treatment option: case report and review of anti-angiogenic treatment options.
    Semenisty V; Naroditsky I; Keidar Z; Bar-Sela G
    BMC Cancer; 2015 May; 15():402. PubMed ID: 25967676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete regression of a non-small cell lung cancer choroidal metastasis with intravitreal bevacizumab.
    D'Antonio C; Viterbo A; Romiti A; Enrici MM; Lauro S; Marchetti P
    J Thorac Oncol; 2012 Feb; 7(2):468-9. PubMed ID: 22252564
    [No Abstract]   [Full Text] [Related]  

  • 7. Vascular-endothelial-growth-factor (VEGF) expression and possible response to angiogenesis inhibitor bevacizumab in metastatic alveolar soft part sarcoma.
    Azizi AA; Haberler C; Czech T; Gupper A; Prayer D; Breitschopf H; Acker T; Slavc I
    Lancet Oncol; 2006 Jun; 7(6):521-3. PubMed ID: 16750504
    [No Abstract]   [Full Text] [Related]  

  • 8. Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.
    Burns TF; Juergens RA
    Oncology (Williston Park); 2010 Nov; 24(13):1223-4, 1226. PubMed ID: 21192562
    [No Abstract]   [Full Text] [Related]  

  • 9. Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma.
    Mascarenhas RC; Sanghvi AN; Friedlander L; Geyer SJ; Beasley HS; Van Thiel DH
    Oncology; 2004; 67(5-6):471-5. PubMed ID: 15714004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab in adult malignant brainstem gliomas.
    Raza S; Donach M
    J Neurooncol; 2009 Nov; 95(2):299-300. PubMed ID: 19506812
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of choroidal neovascularization in pathologic myopia with intravitreal bevacizumab.
    Laud K; Spaide RF; Freund KB; Slakter J; Klancnik JM
    Retina; 2006 Oct; 26(8):960-3. PubMed ID: 17031300
    [No Abstract]   [Full Text] [Related]  

  • 13. More on bevacizumab in hereditary hemorrhagic telangiectasia.
    Oosting S; Nagengast W; de Vries E
    N Engl J Med; 2009 Aug; 361(9):931; author reply 931-2. PubMed ID: 19710496
    [No Abstract]   [Full Text] [Related]  

  • 14. Pulmonary epithelioid hemangioendothelioma.
    Rosengarten D; Kramer MR; Amir G; Fuks L; Berkman N
    Isr Med Assoc J; 2011 Nov; 13(11):676-9. PubMed ID: 22279701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab in first-line treatment of metastatic breast cancer: a viewpoint by David Miles.
    Miles D
    Drugs; 2007; 67(12):1800-1. PubMed ID: 17683177
    [No Abstract]   [Full Text] [Related]  

  • 16. Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma.
    Grover S; Gupta S; Sharma R; Brar VS; Chalam KV
    Br J Ophthalmol; 2009 Feb; 93(2):273-4. PubMed ID: 18617542
    [No Abstract]   [Full Text] [Related]  

  • 17. Multifocal epithelioid hemangioendothelioma: case report of a clinical chamaeleon.
    Bölke E; Gripp S; Peiper M; Budach W; Schwarz A; Orth K; Reinecke P; van de Nes JA
    Eur J Med Res; 2006 Nov; 11(11):462-6. PubMed ID: 17182357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer.
    Willett CG; Boucher Y; di Tomaso E; Duda DG; Munn LL; Tong RT; Chung DC; Sahani DV; Kalva SP; Kozin SV; Mino M; Cohen KS; Scadden DT; Hartford AC; Fischman AJ; Clark JW; Ryan DP; Zhu AX; Blaszkowsky LS; Chen HX; Shellito PC; Lauwers GY; Jain RK
    Nat Med; 2004 Feb; 10(2):145-7. PubMed ID: 14745444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. More on bevacizumab in hereditary hemorrhagic telangiectasia.
    Retornaz F; Rinaldi Y; Duvoux C
    N Engl J Med; 2009 Aug; 361(9):931; author reply 931-2. PubMed ID: 19714790
    [No Abstract]   [Full Text] [Related]  

  • 20. Technology evaluation: bevacizumab, Genentech/Roche.
    Salgaller ML
    Curr Opin Mol Ther; 2003 Dec; 5(6):657-67. PubMed ID: 14755893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.